Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Quinocide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.56 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.56 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.86 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.86 |
| ▸ | THRB | P10828 | 2/20 | 0.86 |
| ▸ | HTT | P42858 | 2/20 | 0.86 |
| ▸ | TDP2 | O95551 | 1/20 | 0.86 |
| ▸ | FGB | P02675 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | GAA | P10253 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 1/20 | 0.86 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.86 |
| ▸ | RECQL | P46063 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinocide SCHEMBL157174 | 0.94 | MEN1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL29720457 | 0.94 | MEN1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL30823571 | 0.93 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL707955 | 0.93 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Quinocide SCHEMBL28060369 | 0.93 | HSP90AA1 (1.00) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Pentaquine SCHEMBL6081373 | 0.86 | HSP90AA1 (0.67) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Phosphoric Acid SCHEMBL11544230 | 0.84 | MEN1 (0.62) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Phosphoric Acid SCHEMBL11546533 | 0.83 | CASP6 (0.94) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| Phosphoric Acid SCHEMBL9719166 | 0.82 | HSP90AA1 (0.65) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL17792862 | 0.80 | HSP90AA1 (0.93) | MEN1KMT2AHSP90AA1HSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064210-A1 | INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) | BLOOD CELL TECHNOLOGIES, LLC (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2022173818-A1 | USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20130053333-A1 | Aminoquinoline Derivatives | CONCERT PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2011091035-A1 | AMINOQUINOLINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-4167638-A | Process for production of 8-NHR quinolines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053333-A1 | Aminoquinoline Derivatives | NQO2, QTRT2, RECQL | ADRB2 2919/4885ADRB1 2608/4885OPRM1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.